| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anti-HIV-1 Antibodies: An Update
|
Promsote, Wanwisa
|
|
|
34 |
2 |
p. 121-132
|
article
|
| 2 |
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
|
Sharman, Jeff P.
|
|
|
34 |
2 |
p. 171-181
|
article
|
| 3 |
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study
|
Joshi, Srishti
|
|
|
34 |
2 |
p. 209-223
|
article
|
| 4 |
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
|
Ebbers, Hans C.
|
|
|
34 |
2 |
p. 225-233
|
article
|
| 5 |
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
|
Zhao, Qi
|
|
|
34 |
2 |
p. 111-119
|
article
|
| 6 |
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
|
Lee, Arnold
|
|
|
34 |
2 |
p. 235-244
|
article
|
| 7 |
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
|
Strand, Vibeke
|
|
|
34 |
2 |
p. 253
|
article
|
| 8 |
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
|
Dutta, Binita
|
|
|
34 |
2 |
p. 159-170
|
article
|
| 9 |
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
|
Cohen, Stanley B.
|
|
|
34 |
2 |
p. 197-207
|
article
|
| 10 |
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
|
Hoy, Sheridan M.
|
|
|
34 |
2 |
p. 245-251
|
article
|
| 11 |
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
|
Haridas, Vikram Muralidhar
|
|
|
34 |
2 |
p. 183-196
|
article
|
| 12 |
Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria
|
Fattizzo, Bruno
|
|
|
34 |
2 |
p. 149-158
|
article
|
| 13 |
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline
|
Klavdianou, Kalliopi
|
|
|
34 |
2 |
p. 133-147
|
article
|
Journal description